KRAS is a frequent oncogenic driver in solid tumors, including non-small cell lung cancer
(NSCLC). It was previously thought to be an" undruggable" target due to the lack of deep …

Cancers harboring mutations in the Kirsten rat sarcoma homolog (KRAS) gene have been
associated with poor prognosis and lack of targeted therapies. KRAS mutations occur in …

The molecular underpinnings that drive the heterogeneity of KRAS-mutant lung
adenocarcinoma are poorly characterized. We performed an integrative analysis of …

Motivation As we move toward an era of precision medicine, the ability to predict patient-
specific drug responses in cancer based on molecular information such as gene expression …

Importance Lung cancer is the leading cause of cancer deaths worldwide, with non–small-
cell lung cancer (NSCLC) constituting more than 80% of all lung cancers. Non–small-cell …

Background Lung cancer has been associated with the highest cancer‐associated mortality
rate in the world. Chemotherapeutic management of cancer necessitates introducing new …

Lung cancer is the leading cause of cancer death in the world and there is no current
treatment able to efficiently treat the disease as the tumor is often diagnosed at an advanced …

We have developed a Drosophila lung cancer model by targeting Ras1 G12V—alone or in
combination with PTEN knockdown—to the Drosophila tracheal system. This led to …

The approval of the first kinase inhibitor, Gleevec, ushered in a paradigm shift for
oncological treatment—the use of genomic data for targeted, efficacious therapies. Since …

Abstract Epigallocatechin-3-gallate (EGCG), the most abundant polyphenol in green tea
extract, has been found to have anticancer activities in various types of cancer. However, the …